David J. Katzelnick, M.D., as clinical and research interests in improving access to quality, evidence-based care for patients who have depression, bipolar disorder and anxiety disorders. Dr. Katzelnick's goal is to integrate mental health providers into primary care practices, making behavioral health care a core component of primary care practices, which will ultimately improve access to mental health care and decrease stigma for both adults and children.
Dr. Katzelnick has lectured extensively on mood and anxiety disorders and ways to improve treatment of mental disorders in real-world settings. He is involved in the Division of Integrated Behavioral Health, which seeks to implement treatments that have been shown to be effective in research into real-world settings.
- Care of Mental, Physical and Substance Use Syndromes (COMPASS). From 2012 to 2015, Dr. Katzelnick served as Mayo Clinic site co-principal investigator of the successful COMPASS Center for Medicare & Medicaid Innovation Grant. The goal of COMPASS is to implement the TEAMCare model for patients with depression and diabetes or cardiovascular disease in primary care clinics and study if this evidence-based model can be sustained in the real world. COMPASS has been implemented in eight states in multiple medical groups, including eight Mayo Clinic locations in Rochester and Jacksonville. Data from this study are being included in the Mayo Model of Community Care.
- Depression Improvement Across Minnesota, Offering a New Direction (DIAMOND). This depression care coordination program is active in all Employee and Community Health (ECH) primary care clinics and has a database containing longitudinal treatment and outcome data for over 8,000 patients with depression. Dr. Katzelnick has been involved in studies analyzing and publishing research based on this dataset.
- Early Management and Evidence-Based Recognition of Adolescents Living With Depression (EMERALD). This innovative program has adapted the DIAMOND depression program to be used for adolescents. Dr. Katzelnick studies the impact of the program on adolescent participant depression severity, suicidality, and patient and provider satisfaction. The results of EMERALD are now being submitted for publication, and the program is being spread to additional ECH clinics.
Significance to patient care
Dr. Katzlenick's aim is to improve care for adults and children with mental illnesses. Evidence overwhelmingly suggests that a collaborative care approach to common mental illnesses is superior to usual care. Dr. Katzelnick realizes that the problem is not a lack of evidence or documentation of a better model, but the need for the adoption of implementation science and dissemination of knowledge to bring collaborative care into practice.
- Co-principal investigator, federally funded COMPASS study, 2012-2015
- Member, National College Depression Partnership, 2007-2009
- Collaborative Partner of the Year Award, Mental Health Association of Wisconsin, 2006
- Co-chair, AAFP/ACP/APA Initiative to Improve Care for Patients With Depression, 2005-2006
- Collaborator, Robert Wood Johnson Breakthrough Series Collaborative — Improving Care for People with Chronic Conditions III, 2000-2001
- Depression co-chair, Institute for Healthcare Improvement, 2000-2001